☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
merck
Merck’s Capvaxive Receives the US FDA’s Accelerated Approval to Prevent Invasive Pneumococcal Disease and Pneumonia in Adults
June 18, 2024
Merck Expands its Ophthalmologic Portfolio Through the Acquisition of EyeBio
May 30, 2024
Merck Reports the Data from P-III (KEYNOTE-522) Study of Keytruda for Treating Triple Negative Breast Cancer (TNBC)
May 29, 2024
Merck Reports Results from the P-III (KEYNOTE-B21) Study of Keytruda Plus Chemotherapy for Endometrial Cancer
May 9, 2024
Merck Reports the P-III (KEYNOTE-811) Study Data of Keytruda Plus Trastuzumab and Chemotherapy for G/GEJ Adenocarcinoma
May 2, 2024
Merck Reports Data from the P-III (STRIDE-10) Trial of V116 Pneumococcal Conjugate Vaccine for Adults
April 30, 2024
Load more...
Back to Home